Placentas, usually discarded after childbirth, are a rich source of stem cells, collagen, and cytokines, giving them significant potential for alleviating pain, reducing inflammation, and promoting the healing of chronic wounds. In the U.S., there are approximately 4 million births each year, yet only a small fraction - less than 1% - of placental blood and tissue is preserved. However, there is growing awareness of the vast potential of placental tissue.
The stock we are bringing to your attention today is that of MiMedx Group Inc. (MDXG), a pioneer in placental biologics providing a portfolio of products for applications in wound care, burn, and surgical sectors of healthcare.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com